Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSP90AB1 | P08238 | 3/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.48 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | HSP90AA1 | P07900 | 2/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | ADCY10 | Q96PN6 | 6/20 | 0.42 |
| ▸ | GHSR | Q92847 | 3/20 | 0.42 |
| ▸ | NUDT1 | P36639 | 1/20 | 0.40 |
| ▸ | DHODH | Q02127 | 1/20 | 0.40 |
| ▸ | DHFR | P00374 | 1/20 | 0.40 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3718901 | 0.82 | HSP90AB1 (0.74) | HSP90AB1SMN1; SMN2HSP90AA1KDM4EADCY10 | |
| SCHEMBL18004111 | 0.81 | TSHR (0.47) | HSP90AB1SMN1; SMN2TSHRNPC1RAB9A | |
| SCHEMBL1983321 | 0.81 | TSHR (0.47) | TSHRKDM4EGHSRNUDT1 | |
| SCHEMBL16398644 | 0.80 | L3MBTL1 (0.55) | HSP90AB1SMN1; SMN2TSHRNPC1RAB9A | |
| SCHEMBL10901993 | 0.79 | RAB9A (0.56) | HSP90AB1SMN1; SMN2HSP90AA1KDM4ENPC1 | |
| SCHEMBL18399214 | 0.79 | TSHR (0.44) | HSP90AB1SMN1; SMN2TSHRNPC1RAB9A | |
| SCHEMBL3715977 | 0.79 | HSP90AB1 (0.56) | HSP90AB1SMN1; SMN2HSP90AA1KDM4EADCY10 | |
| SCHEMBL18003960 | 0.78 | TSHR (0.43) | HSP90AB1SMN1; SMN2TSHRNPC1RAB9A | |
| SCHEMBL3718771 | 0.77 | HSP90AB1 (0.49) | HSP90AB1SMN1; SMN2HSP90AA1KDM4ERAB9A | |
| SCHEMBL3930094 | 0.76 | NUDT1 (0.62) | HSP90AB1SMN1; SMN2TSHRHSP90AA1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2516420-B1 | AMINOALKYLPYRIMIDINE DERIVATIVES AS HISTAMINE H4 RECEPTOR ANTAGONISTS | MEDICIS PHARMACEUTICAL CORP (US) | 2018-08-22 | — | — | EP | disclosed |
| CN-102803248-B | As the aminoalkyl pyrimidine of histamine H 4 receptor antagonist | MEDICIS PHARMACEUTICAL CORP. (US) | 2015-09-16 | — | — | CN | disclosed |
| US-8901146-B2 | Aminoalkylpyrimidine derivatives as histamine H4 receptor antagonists | MEDICIS PHARMACEUTICAL CORPORATION (US) | 2014-12-02 | — | — | US | disclosed |
| US-20130018031-A1 | AMINOALKYLPYRIMIDINE DERIVATIVES AS HISTAMINE H4 RECEPTOR ANTAGONISTS | MEDICIS PHARMACEUTICAL CORPORATION (US) | 2013-01-17 | — | — | US | disclosed |
| CN-102803248-A | Aminoalkylpyrimidine derivatives as histamine H4 receptor antagonists | PALAU PHARMA SA | 2012-11-28 | — | — | CN | disclosed |
| EP-2516420-A1 | AMINOALKYLPYRIMIDINE DERIVATIVES AS HISTAMINE H4 RECEPTOR ANTAGONISTS | Palau Pharma, S.A. (ES) | 2012-10-31 | — | — | EP | disclosed |
| WO-2011076878-A1 | AMINOALKYLPYRIMIDINE DERIVATIVES AS HISTAMINE H4 RECEPTOR ANTAGONISTS | PALAU PHARMA, S.A. (ES) | 2011-06-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130018031-A1 | AMINOALKYLPYRIMIDINE DERIVATIVES AS HISTAMINE H4 RECEPTOR ANTAGONISTS | HRH4, HRH2, HRH3 | HSP90AB1 2975/4885SMN1; SMN2 4871/4885TSHR 842/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.